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Mycobacterium tuberculosis, the causative agent of tuberculosis, is one of the leading
causes of human deaths due to a single infectious agent. M. tuberculosis infection of
the host initiates a local inflammatory response, resulting in the production of a range
of inflammatory factors at the site of infection. These inflammatory factors may come
in direct contact with M. tuberculosis and immune cells to activate different signaling
pathways. One such factor produced in excess during inflammation is a phospholipid
compound, Platelet Activating Factor C-16 (PAF C-16). In this study, PAF C-16 was
shown to have a direct inhibitory effect on the growth of Mycobacterium bovis BCG
(M. bovis BCG) and Mycobacterium smegmatis (M. smegmatis) in a dose- and time-
dependent manner. Use of a range of PAF C-16 structural analogs, including the
precursor form Lyso-PAF, revealed that small modifications in the structure of PAF C-
16 did not alter its mycobacterial growth inhibitory properties. Subsequent experiments
suggested that the attachment of aliphatic carbon tail via ether bond to the glycerol
backbone of PAF C-16 was likely to play a vital role in its growth inhibition ability against
mycobacteria. Fluorescence microscopy and flow cytometry using Propidium iodide (PI)
indicated that PAF C-16 treatment had a damaging effect on the cell membrane of
M. bovis BCG and M. smegmatis. Furthermore, the growth inhibitory effect of PAF C-
16 was partially mitigated by treatment with membrane-stabilizing agents, α-tocopherol
and Tween-80, which further suggests that the growth inhibitory effect of PAF C-16 was
mediated through bacterial cell membrane damage.
Keywords: platelet activating factor C-16, PAF analogs, tuberculosis, Mycobacterium tuberculosis,
Mycobacterium bovis BCG, Mycobacterium smegmatis, bacterial cell membrane
INTRODUCTION
Tuberculosis (TB) is an infectious disease, caused by the acid-fast bacillus, Mycobacterium
tuberculosis. According to the World Health Organization (WHO), TB is one of the leading causes
of human mortality, resulting in more than one million human deaths each year. Approximately
10.4 million new cases of TB were reported worldwide in the year 2016 (World Health Organization
[WHO], 2017). It is estimated that about one-third of the world’s population (1.7 billion
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people) is latently infected with M. tuberculosis, a condition
with no active disease symptoms due to containment of the
pathogen by the host immune system (Houben and Dodd,
2016). This latent infection with M. tuberculosis provides a huge
reservoir for reactivation into active TB and its spread across
the globe. TB continues to be a major health problem due to
the non-availability of an effective vaccine. The only preventive
vaccine against TB is BCG, which is almost a century old
and not effective in controlling the spread of M. tuberculosis
infections in economically active adult humans, which comprises
the major population of TB patients in developing countries
(Sepulveda et al., 1992; Colditz et al., 1994; Aronson et al.,
2004; Lahey and von Reyn, 2016). New challenges, such as cases
of HIV-1 and M. tuberculosis co-infection (Daley et al., 1992),
multidrug-resistant tuberculosis (MDR-TB) (Espinal et al., 2000),
and extensively drug resistant tuberculosis (XDR-TB) (Jain and
Mondal, 2008; Liu et al., 2011) have compounded the severity of
the problem, and therefore, novel therapeutic interventions are
required to control TB.
Infection of a host by M. tuberculosis activates the host’s
immune system resulting in a localized inflammatory response
(Cooper and Flynn, 1995; Giacomini et al., 2001). This causes
an increase in blood flow and changes in vascular permeability,
resulting in the leakage of several proteinaceous and non-
proteinaceous factors and the migration of cellular components
from the blood to the site of infection (Sherwood and Toliver-
Kinsky, 2004; Clark et al., 2007). In addition to the plasma-
derived factors, complement proteins such as C1q and lipid
compounds, such as PAF C-16 and Lyso-PAF, are also synthesized
by inflammatory cells such as macrophages at the site of infection
(Camussi et al., 1987; Kaul and Loos, 1995). These factors are
likely to come in contact with the pathogens and immune cells,
and thus, may modulate the outcome of the infection.
PAF C-16 or PAF-acether, a membrane-derived phospholipid
is chemically known as 1-O-alky-2-acetyl-sn-glycero-3-
phosphocholine. PAF C-16 is normally present in low amounts
in human serum (approximately 127 pg/ml); however, its
concentration increases by six-fold during allergic reactions
(Vadas et al., 2013). PAF C-16 is produced by a range of cells,
including platelets, neutrophils, macrophages, endothelial and
mast cells (Alam et al., 1983; Bussolino et al., 1986; Schleimer
et al., 1986; Leaver et al., 1990; Biffl et al., 1996; Gardiner
et al., 1999). PAF C-16 is synthesized by two distinct pathways;
the remodeling pathway and the de novo synthesis pathway
(Prescott et al., 1990). The remodeling pathway is the major
PAF C-16 synthesis pathway used by activated inflammatory
cells and involves the modification of membrane ether-linked
phospholipids by the enzymes PLA2 and acetyl coenzyme A
acetyltransferase in a two-step process to produce PAF C-16
(Shindou et al., 2007).
PAF C-16 binds to specific transmembrane G-protein coupled
receptors, known as PAF receptor (PAFR), on the plasma
membrane of target cells (Honda et al., 2002; Ishii et al., 2002).
Binding of PAF C-16 to PAFR results in the activation of different
signal transduction mechanisms such as phosphatidylinositol-
calcium second messenger system, and the activation of different
kinases including protein tyrosine kinase, mitogen-activated
protein kinases and protein kinase C pathways (Honda et al.,
2002).
PAF C-16 is endowed with diverse biological activities
including its well-known ability to cause platelet aggregation
(Chignard et al., 1980a,b). PAF C-16 also has important roles
in inflammatory and allergic responses (Henderson et al., 2000).
PAF C-16 induces apoptosis in neuronal and epidermal cells
(Barber et al., 1998; Brewer et al., 2002; Ryan et al., 2008),
causes the production of reactive oxygen and nitrogen species
by macrophages (Hartung et al., 1983; Rouis et al., 1988; Aliberti
et al., 1999; Borges et al., 2017), and plays an important role in
angiogenesis (Seo et al., 2004). Dysregulated production of PAF
C-16 has been associated with a number of diseases including
multiple sclerosis (Hostettler et al., 2002), thrombosis (Mueller
et al., 1995), myocardial infarctions (Montrucchio et al., 2000),
rheumatoid arthritis (Hilliquin et al., 1995), bronchial asthma
(Cuss et al., 1986), acute pancreatitis, and inflammatory bowel
disease (Rosam et al., 1986). PAFR antagonists bind to PAFR
with high affinity and have been shown to successfully inhibit
certain pathological processes in asthma, cardiac, and circulatory
disorders that are driven by PAF C-16 (Singh et al., 2013).
There is a limited information available on the direct anti-
microbial activity of PAF C-16. PAF C-16 has been shown to
inhibit the growth of Gram-positive bacteria in cultures, but not
Gram-negative bacteria (Steel et al., 2002). However, the direct
anti-mycobacterial role of PAF C-16 has not been investigated. In
this study, exogenous PAF C-16 and its structural analogs were
examined for their direct effect on mycobacterial growth using
M. bovis BCG (Pasteur 1173P2) and M. smegmatis (mc2 155)
as models for M. tuberculosis. We report that PAF C-16 and a
number of PAF C-16 structural analogs inhibited the growth of
both M. bovis BCG and M. smegmatis. The active portion of PAF
C-16 responsible for mycobacterial growth inhibition and the





choline), Lyso-PAF C-16 (1-O-hexadecyl-2-hydroxy-sn-
glyceryl-3-phosphorylcholine), PAF C-18 (1-O-octadecyl-
2-O-acetyl-sn-glyceryl-3-phosphorylcholine), Hexanolamino
PAF C-16 [1-O-hexadecyl-2-O-acetyl-sn-glyceryl-3-
phosphoryl (N,N,N-trimethyl) hexanolamine], 2-O-methyl
PAF C-16 (1-O-hexadecyl-2-O-methyl-sn-glyceryl-3-phosphoryl
choline), Pyrrolidino PAF C-16 (1-O-hexadecyl-2-O-acetyl-sn-
glyceryl-3-phosphoryl-N-methyl-pyrrolidinium ethanol), and
Miltefosine (1-hexadecylphosphorylcholine) were obtained from
Cayman Chemical Company, United States (Figure 3). 1-O-
hexadecyl-sn-glycerol (Bachem) was obtained from Cambridge
Biosciences, United Kingdom, Palmitic acid (Hexadecanoic
acid), Vitamin E [(±)-α-Tocopherol] and Phosphocholine
chloride calcium salt tetrahydrate were purchased from Sigma-
Aldrich Company, United States, and Hexadecyl lactate was
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purchased from Santa Cruz Biotechnology, United States. All
other chemicals used in the experiments were of analytical grade.
Stock solutions of phospholipids and fatty acids were prepared
in ethanol (10 mg/ml). Miltefosine was dissolved in PBS
(10 mg/ml), Hexadecyl lactate in DMSO (10 mg/ml), and
Phosphocholine chloride calcium salt tetrahydrate in water
(10 mg/ml). Appropriate solvent controls were included in all
the experiments involving PAF C-16, its structural analogs or any
other chemical compound used with bacteria.
Mycobacterial Strains and Growth
Conditions
Liquid cultures of M. smegmatis (mc2 155) were grown in
Luria-Bertani (LB) broth (Lennox; Sigma Aldrich) containing
50 µg/ml carbenicillin (Fisher Chemical), 0.15% (v/v) glycerol
and 0.1% (v/v) tween-80 in a shaking incubator at 37◦C until the
O.D(600nm) reached 0.8–0.9. The number of M. smegmatis colony
forming units (CFUs) per ml was determined by plating different
dilutions of the bacterial stock on LB agar plates in triplicates and
counting the number of CFUs after incubation at 37◦C for 72 h.
Liquid cultures of M. bovis BCG (Pasteur 1173P2) were grown
in Middlebrook 7H9 broth (Sigma Aldrich), supplemented with
10% (v/v) albumin dextrose catalase (ADC) and 0.2% (v/v)
tween-80. ADC was prepared by dissolving 5 g of bovine albumin
fraction V (Fisher Chemical), 2 g dextrose (Fisher Chemical),
0.85 g sodium chloride (Fisher Chemical) and 4 mg catalase
from bovine liver (Sigma Aldrich) in 100 ml of sterile water and
the solution was passed through a 0.22 µm filter. The growth
cultures were kept in a shaking incubator at 37◦C for 2–3 weeks
until the O.D(600nm) reached 0.8–0.9. The number of CFUs per
ml for stock M. bovis BCG was determined by plating different
dilutions of the bacterial stock on 7H10 plates (BD Biosciences)
in triplicates and counting the number of CFUs after incubation
at 37◦C for 2–3 weeks.
Mycobacterial Growth Inhibition Assays
Appropriately diluted M. bovis BCG and M. smegmatis
(2.5 × 104) in suspensions of 1ml 7H9 or LB broth, respectively,
were exposed to a range of concentrations of PAF C-16 or PAF
C-16 analogs (10–100 µg/ml) for 2 h at 37◦C with mixing every
15 min. Appropriate solvent controls for the test chemicals were
also included in all the experiments. After incubation, 200 µl of
bacterial suspensions from test compound treated and solvent
control tubes were plated on agar plates in triplicate and viable
colony counting methods were used to detect the direct growth
inhibitory effects of PAF C-16 and its analogs. M. smegmatis was
seeded on LB agar plates and incubated for 72 h while 7H10 plates
were used for M. bovis BCG and incubated for 3–4 weeks at 37◦C
after which the CFUs were counted by the naked eye.
The above described protocol was also used to investigate
in vitro direct growth inhibitory effect of Palmitic acid (10–
100 µg/ml), Phosphocholine chloride calcium salt tetrahydrate
(10–100 µg/ml), 1-O-hexadecyl-sn-glycerol (10–100 µg/ml),
Miltefosine (10–100 µg/ml), and Hexadecyl lactate (10–
100 µg/ml) in order to localize the biologically active portion of
PAF C-16 contributing to the growth inhibition.
Additional experiments to determine the effect of incubation
time on the growth inhibitory concentration of PAF C-16
against M. bovis BCG and M. smegmatis were performed in a
similar manner. However, lower concentrations of PAF C-16
(1–25 µg/ml) were also used and the incubation periods with
bacteria were increased to 6, 12, and 24 h.
Fluorescence Microscopy and Flow
Cytometry to Detect Damage to the
Mycobacterial Cell Membrane
Propidium Iodide (PI) (BioLegend, San Diego, CA,
United States), a nucleic acid binding fluorescent dye, was
used to detect damage to the mycobacterial cell membrane by
using fluorescence microscopy and flow cytometry. One ml of
M. bovis BCG or M. smegmatis [O.D(600nm) = 0.9] from fresh
culture was washed with PBS via centrifugation (5000 rpm,
10 min), resuspended in 1ml of broth culture media, and then
incubated with 100 µg PAF C-16 for 2 h at 37◦C with mixing
every 15 min. Ethanol treated (10 µl/ml for 2 h) and heat killed
(100◦C for 10 min) bacterial samples were used as solvent control
and positive control, respectively. Next, PAF C-16 treated test
and untreated control bacterial samples were washed twice with
PBS (5000 rpm for 10 min) and then stained with PI (1 µg/ml)
for 20 min at room temperature in dark. The excess dye was
removed by washing with PBS.
For fluorescence microscopy, the bacterial pellets were
resuspended in 100 µl of PBS, and 5 µl of bacteria from each
condition was examined at 400× magnification using a Leica
DM4000 R© fluorescence microscope. For flow cytometry, the
bacterial pellets were resuspended in 250 µl of PBS and 25000
events were acquired using ACEA NovoCyte R© Flow Cytometer;
the acquired data was analyzed by NovoExpress R© software. To
determine the percentage of PI stained bacteria, first the solvent
control (10 µl ethanol/ml of bacterial suspension) stained with PI
was analyzed on a density plot by applying gates such that most
of the bacterial population was negative for PI. The same gates
were then applied on the density plots for heat-killed (100◦C for
10 min) positive control and 100 µg/ml PAF C-16 treated test
conditions.
Effect of α-Tocopherol and Tween-80 on
PAF C-16 Induced Growth Inhibition
α-tocopherol and tween-80 were used to determine if they can
mitigate the PAF C-16 induced bacterial growth inhibition as
shown previously (Kagan, 1989; Li et al., 2011). M. smegmatis
(2.5 × 104) and M. bovis BCG (2.5 × 104) were resuspended
in 1ml broth medium and treated with either 100 µg/ml
α-tocopherol or 1% v/v tween-80 for 1h at 37◦C. After 1 h, PAF
C-16 (100 µg/ml bacterial suspension) was added to the samples
and incubated at 37◦C for 2 h with mixing after every 15 min.
Solvent (20 µl ethanol/ml bacterial suspension), α-tocopherol
(100 µg/ml bacterial suspension), tween-80 (1% v/v bacterial
suspension) and PAF C-16 (100 µg/ml bacterial suspension)
treated M. smegmatis or M. bovis BCG were included as controls.
After incubation, 200 µl of bacterial suspension from the test
and control tubes was seeded on agar plates in triplicate and the
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CFUs were counted using viable colony counting method for each
condition.
Statistical Analysis
All the experiments were repeated 3–6 times. The data for growth
inhibition assays were expressed as mean ± standard error of
means (S.E.M), and the solvent treated samples were considered
100% bacterial survival. Statistical analysis was performed using
GraphPad Prism R© software (Version 5.01) to determine the level
of significance (p-value) by applying non-parametric multiple
comparison Kruskal-Wallis test on ranks and individual data-
sets were compared using post hoc Dunn’s multiple comparison
test. For comparison of two particular datasets, non-parametric
Mann-Whitney test was used. A p-value of less than or equal to
0.05 (p ≤ 0.05) was considered to be significant. On the graphs
p ≤ 0.05 is denoted by ∗, p ≤ 0.01 by ∗∗ and p ≤ 0.001 by ∗∗∗.
RESULTS
PAF C-16 Inhibits M. smegmatis and
M. bovis BCG Growth in a
Dose-Dependent Manner
Treatment of M. smegmatis and M. bovis BCG with PAF C-16
(10, 25, 50, and 100 µg/ml) for 2 h resulted in a dose-dependent
growth inhibition, as evident from the decrease in the number of
surviving CFUs when compared with PAF C-16 solvent control
(10 µl ethanol/ml bacterial culture) (Figures 1A,B). PAF C-16
treatment of M. smegmatis and M. bovis BCG at the lower
range of concentrations (10 and 25 µg/ml) showed 15–40%
reduction in the number of CFUs. The number of M. smegmatis
CFUs after treatment with 50 µg/ml PAF C-16 on an average
decreased by 65%, whereas, 100 µg/ml PAF C-16 treatment
caused 97% reduction (Figure 1A). Similar results were obtained
for M. bovis BCG where 50 µg/ml and 100 µg/ml PAF C-16
treatment on an average reduced the number of surviving CFUs
by 66% and 88%, respectively, when compared to the number
of CFUs from the solvent control (Figure 1B). Although a
trend of M. smegmatis and M. bovis BCG growth inhibition
was seen in all the experiments using the above range of PAF
C-16 concentrations, only PAF C-16 at the concentration of
50 µg/ml (p ≤ 0.01) and 100 µg/ml (p ≤ 0.001) reached
statistical significance using stringent non-parametric Dunn’s
multiple comparison test.
PAF C-16 Inhibits M. smegmatis and
M. bovis BCG Growth in a
Time-Dependent Manner
To assess the effect of PAF C-16 exposure time on the growth
inhibition of M. smegmatis and M. bovis BCG, bacteria were
treated for extended durations of 6, 12 and 24 h with PAF C-16
(1–25 µg/ml) (Figures 2A,B). It was observed that in addition
to concentration, the growth inhibition of both M. smegmatis
and M. bovis BCG by PAF C-16 was also dependent on the
treatment duration. PAF C-16 treatment at 5 µg/ml or at higher
concentrations was effective in inhibiting the growth of both
FIGURE 1 | Effect of PAF C-16 treatment on M. smegmatis and M. bovis
BCG survival in vitro. Number of surviving colony forming units of
M. smegmatis (A) and M. bovis BCG (B) after 2 h of treatment with the
indicated concentrations of PAF C-16. Data is expressed in terms of percent
survival where solvent control is taken as 100% survival and different PAF
C-16 treated test conditions are compared to it. Each bar represents the
average of six individual experiments performed in triplicate and the error bars
show the standard error of mean values (±SEM). Statistically significant
differences from the solvent control by Kruskal-Wallis test with post hoc
Dunn’s multiple comparison test are indicated ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001.
M. smegmatis and M. bovis BCG by ≥50% at all the three time
points. At 6 h, PAF C-16 treatment at a concentration of 5 µg/ml
caused a reduction of 55% in the number M. smegmatis CFUs
when compared to the solvent control. The PAF C-16 caused
M. smegmatis growth inhibition at 5 µg/ml increased to ≥95%,
as evident from the decrease in CFUs when the treatment times
were increased to 12 and 24 h (Figure 2A). Similar results
were obtained with M. bovis BCG. At 6 h, PAF C-16 at the
concentration of 5 µg/ml reduced the number of M. bovis BCG
CFUs by 51% which increased to 85% after 12 h treatment and
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FIGURE 2 | Inhibitory effects of PAF C-16 on M. smegmatis and M. bovis
BCG growth at increased incubation durations. Number of surviving colony
forming units of M. smegmatis (A) and M. bovis BCG (B) after 6, 12, and 24 h
of treatment with indicated concentrations of PAF C-16. Data is expressed in
terms of percent survival where solvent control is taken as 100% survival.
Each data point represents the average of four individual experiments
performed in triplicate and the error bars show the standard error of mean
values (±SEM).
finally reached 96% after 24 h (Figure 2B). PAF C-16 at the
concentration of 2.5 µg/ml after 6 h treatment on an average
caused 14% and 12% reduction in the number of M. smegmatis
and M. bovis BCG CFUs, respectively, which increased to ∼29%
after 24 h treatment. Furthermore, 1 µg/ml PAF C-16 showed
negligible growth inhibition at all the three time points tested
against both M. smegmatis and M. bovis BCG.
Subsequent experiments with PAF C-16 and its structural
analogs were performed at concentrations ranging from 10 to
100 µg/ml with treatment duration of 2 h, because we established
the growth inhibition of M. smegmatis and M. bovis BCG at the
lowest concentration of 5 µg/ml PAF C-16 at increased treatment
durations.
PAF C-16 Analogs Show a Similar
Growth Inhibitory Effect Against
M. smegmatis and M. bovis BCG
Different PAF C-16 structural analogs, including the naturally
occurring precursor form Lyso-PAF C-16, PAF C-18 and
Hexanolamino PAF C-16 as well as synthetic analogs, such as
2-O-methyl PAF C-16 and Pyrrolidino PAF C-16 were tested
against both M. smegmatis and M. bovis BCG in order to assess
the impact of small modifications of the structure of PAF C-16
on the in vitro bacterial growth inhibition potential (Figure 3).
PAF C-16 structural analogs used were selected such that each
analog represented a change in different functional groups when
compared to PAF C-16. These PAF C-16 structural analogs were
able to inhibit the growth of bothM. smegmatis andM. bovis BCG
in a dose-dependent manner, when tested at the concentrations
ranging between 10 and 100 µg/ml (Figures 4A,B). M. smegmatis
and M. bovis BCG growth inhibition (p ≤ 0.01–p ≤ 0.001) was
significant at 50 µg/ml (≤50% reduction in CFUs) and 100 µg/ml
(≤90% reduction in CFUs) for all PAF C-16 analogs tested.
Furthermore, the mycobacterial growth inhibition potency of
these PAF C-16 structural analogs was comparable to PAF C-16.
This showed that small alterations in the structure of PAF C-
16 did not affect its direct growth inhibitory potential against
mycobacteria.
Structural Dissection of PAF C-16 to
Localize the Anti-microbial Active
Portion
To localize the biologically active portion of PAF C-16
that contributed to its growth inhibitory properties against
mycobacteria, compounds with structures similar to different
portions of PAF C-16 (Figure 5) were investigated for their direct
mycobacterial growth inhibitory potential using M. smegmatis as
a model. Palmitic acid (hexadecanoic acid) having a linear 16-
carbon atoms chain similar to the carbon tail of PAF C-16 in
the number of carbon atoms, was tested to determine the role
of the carbon chain in the growth inhibition activity of PAF C-
16. However, Palmitic acid (10–100 µg/ml) did not show any
inhibitory effect on M. smegmatis growth; in fact, it showed
a slight growth enhancing effect (Figure 6). Phosphocholine
chloride calcium tetrahydrate salt with a structure resembling the
phosphocholine head region of PAF C-16 also did not show any
direct inhibitory effect on the growth of M. smegmatis (Figure 6).
Finally, 1-O-hexadecyl sn-glycerol, a compound with a 16-carbon
atoms tail attached via ether bond to a glycerol backbone as
in PAF C-16, showed direct dose-dependent growth inhibition
of M. smegmatis following 2 h treatment (Figure 6). This
suggested that the attachment of a carbon tail via an ether linkage
may be important for the anti-mycobacterial characteristics of
PAF C-16. Further experiments with other compounds, such as
miltefosine and hexadecyl lactate, each having a 16-carbon atoms
tail attached via ester linkage to a phosphate and lactyl group,
respectively, also revealed growth inhibition of M. smegmatis
(Figure 6).
PAF C-16 Causes Damage to the
Mycobacterial Cell Membrane
Fluorescence microscopy and flow cytometry were performed to
assess the damaging effect of PAF C-16 on the cell membrane
integrity of mycobacteria. The cell membrane integrity was
determined by using a nucleic acid binding fluorescent dye,
Propidium Iodide (PI). PI only enters the bacteria when the cell
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FIGURE 3 | Chemical structures of PAF C-16 and its structural analogs. Each analog has a small modification in the structure as compared to naturally occurring
PAF C-16 which is highlighted in the red circles.
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FIGURE 4 | Comparison of the levels of growth inhibition by different PAF
C-16 analogs and PAF C-16 for M. smegmatis and M. bovis BCG. Number of
surviving colony forming units of M. smegmatis (A) and M. bovis BCG (B)
after 2 h treatment with indicated concentrations of different PAF C-16
analogs and PAF C-16. The data is expressed as percentage survival where
solvent control is taken as 100% survival. Each data point represents the
average of three individual experiments performed in triplicate and the error
bars show the standard error of mean values (±SEM).
membrane is damaged while bacteria with intact cell membranes
are impermeable to this dye (Cox et al., 2000).
The qualitative analysis of M. smegmatis and M. bovis BCG
by fluorescence microscopy following treatment with 100 µg/ml
PAF C-16 for 2 h revealed loss of membrane integrity, as
determined by positive staining with PI (Figures 7C,F). No PI
staining was observed in the solvent control (10 µl ethanol/ml
of bacterial suspension), suggesting that the bacterial membrane
was intact (Figures 7A,D). Heat-killed (100◦C for 10 min)
M. smegmatis and M. bovis BCG were also included as a positive
control and majority of the bacteria stained positively with
PI (Figures 7B,E). These results from fluorescence microscopy
suggested that PAF C-16 had a damaging effect on the cell
membranes of both M. smegmatis and M. bovis BCG that can lead
to the growth inhibition of these bacteria.
To further quantify the percentage of injured/dead bacteria,
flow cytometry was performed using M. smegmatis and M. bovis
BCG treated with 100 µg/ml PAF C-16 for 2 h. It was
observed that ∼50% of M. smegmatis were stained with PI
following treatment with PAF C-16, whereas, only 2% of
M. smegmatis were stained with PI in the solvent control and
91% staining was observed for the positive control heat-killed
M. smegmatis (Figures 8A–C). Similar results were obtained
with M. bovis BCG; 100 µg/ml PAF C-16 treatment resulted
in ∼41% of bacteria being stained with PI as compared to
2% PI positive staining in solvent control and 72% staining
in heat-killed M. bovis BCG (Figures 8D–F). The histogram
overlays (Figures 8G,H) showed a more than four-fold increase
in the mean channel fluorescence (MeanX) for PAF C-16 treated
M. smegmatis (MeanX = 318) and M. bovis BCG (MeanX = 135)
when compared to the solvent only controls for M. smegmatis
(MeanX = 74) and M. bovis BCG (MeanX = 27), respectively.
These flow cytometry results reaffirmed the notion that PAF C-
16 induced growth inhibition in M. smegmatis and M. bovis BCG
was through damage to their cell membrane.
α-Tocopherol and Tween-80 Prevent the
Growth Inhibitory Effect of PAF C-16 on
Mycobacteria
Since PAF C-16 showed damaging effects on both M. smegmatis
and M. bovis BCG cell membranes, compounds such as
α-tocopherol and tween-80 were used to assess whether they
can mitigate the growth inhibitory effect of PAF C-16, and
thus, have protective effects on mycobacteria. Both α-tocopherol
and tween-80 have previously been shown to reduce the anti-
bacterial activity of hydrophobic compounds such as fatty acids,
phospholipids and antibiotics like rifampicin (Kagan, 1989;
Li et al., 2011; Nielsen et al., 2016). The addition of either
α-tocopherol (100 µg/ml) or tween-80 (1% v/v) to M. smegmatis
or M. bovis BCG suspension for 1 h prior to PAF C-16
(100 µg/ml) treatment partially mitigated the inhibitory effect of
PAF C-16 on the growth of bacteria as indicated by the increase
in number of surviving CFUs on the agar plates when compared
with the number of CFUs from bacteria treated with 100 µg/ml
PAF C-16 only (Figures 9A–C). Furthermore, both α-tocopherol
and tween-80 did not show any direct effect on the growth of
either M. smegmatis or M. bovis BCG on their own.
DISCUSSION
PAF C-16 belongs to a class of single-chained ether linked
lipids and is produced by a variety of immune cells including
monocytes, macrophages (Elstad et al., 1988) and neutrophils
(Lynch et al., 1979). The production of PAF C-16 is enhanced
several fold at the site of infection, where it is available to interact
with invading pathogens (Huseyinov et al., 1999). However,
there is limited information regarding the direct effects of
this pro-inflammatory phospholipid on the growth of bacterial
pathogens both in vivo and in vitro. A previous study showed
that PAF C-16 can directly inhibit the growth of Gram-positive
bacteria (Staphylococcus aureus and Staphylococcus epidermidis)
in vitro, without affecting the growth of Gram-negative bacteria
(Escherichia coli and Pseudomonas aeruginosa) (Steel et al., 2002).
In the current study, we have shown, for the first time, that PAF
C-16 and its structural analogs can directly inhibit the growth of
mycobacteria using M. smegmatis and M. bovis BCG as model
organisms, in a dose- and time-dependent manner in vitro.
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FIGURE 5 | Chemical structures of Palmitic acid, Phosphocholine chloride calcium tetrahydrate, 1-O-Hexadecyl-sn-glycerol, Miltefosine, and Hexadecyl lactate.
We first investigated the effect of PAF C-16 on the growth
of M. smegmatis and M. bovis BCG at various concentrations
(10–100 µg/ml) and for a shorter treatment duration (2 h),
which revealed a decrease in the surviving bacterial CFUs in
a dose-dependent manner, suggesting that PAF C-16 had a
direct growth inhibitory effect in vitro. Since PAF C-16 at
higher concentrations can have certain adverse side effects
on the host (Stafforini et al., 2003), we further investigated
the effect of PAF C-16 on M. smegmatis and M. bovis BCG
growth at lower concentrations (1–25 µg/ml) and at increased
treatment durations of 6, 12 and 24 h. We observed that
this compound was effective at a concentration as low as
5 µg/ml after 6 h of treatment. In order to get an insight
into the structure-function relationships of PAF C-16, different
structural analogs were assessed in vitro for their direct growth
inhibitory potential against M. smegmatis and M. bovis BCG.
PAF C-16 analogs have minor but subtle structural modifications
such as variations in functional groups or carbon tail length
(Tence et al., 1981; Prescott et al., 1990). Previous studies
with PAF C-16 analogs in mammalian systems have shown
that small structural modifications can alter the biological
activity of PAF C-16 to varying degrees (Shigenobu et al.,
1985; O’Flaherty et al., 1987; Rose et al., 1990; Stewart
and Grigoriadis, 1991). These PAF C-16 analogs have not
been investigated for their direct effect on the growth of
mycobacteria.
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FIGURE 6 | Effect of Palmitic acid, Phosphocholine chloride calcium tetrahydrate, 1-O-hexadecyl-sn-glycerol, Miltefosine, and Hexadecyl lactate on M. smegmatis
survival. The data is expressed as percentage where solvent control is taken as 100% survival. Each data point represents the average of three individual
experiments performed in triplicate and the error bars show the standard error of mean values (±SEM).
FIGURE 7 | Fluorescence microscopy to detect the effect of PAF C-16 treatment on M. smegmatis and M. bovis BCG cell membrane integrity. M. smegmatis (A–C)
and M. bovis BCG (D–F) treated with PAF C-16 (100 µg/ml) or solvent control (10 µl/ml ethanol) for 2 h and heat killed (100◦C, 10 min) as a positive control were
stained with the nucleic acid binding dye propidium iodide and imaged at 400× magnification in bright field and CY3 (PI) channels. Panels show a merger of the two
channels. (A,D) are solvent treated negative control, (B,E) are heat treated positive control, (C,F) are PAF C-16 treated test.
Lyso-PAF C-16, the precursor form of naturally produced
PAF C-16, has a hydroxyl group at position sn-2 instead of
an acetyl group and is considered to be biologically inactive
(Pendino et al., 1993; Aliberti et al., 1999; Montrucchio et al.,
2000). In our experiments, however, Lyso-PAF was effective
in inhibiting the growth of both M. smegmatis and M. bovis
BCG at the level similar to PAF C-16. Since Lyso-PAF is the
inactive precursor form and does not possess most of the side
effects associated with PAF C-16, this compound may have
therapeutic potential and needs further investigation for its
anti-M. tuberculosis properties. Similar mycobacterial growth
inhibition results were obtained with other PAF C-16 structural
analogs including PAF C-18 (18 carbon atoms chain at sn-
1), Hexanolamino PAF C-16 (additional 4-carbon atoms chain
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FIGURE 8 | Flow cytometric analysis to determine cell membrane integrity of PAF C-16 treated M. smegmatis and M. bovis BCG. Flow cytometry density plots for
M. smegmatis (A–C) and M. bovis BCG (D–F) treated with PAF C-16 or solvent control for 2 h and heat killed positive control after staining with propidium iodide.
Density plots (A,D) are solvent treated (10 µl/ml ethanol) negative control, density plots (B,E) are heat treated (100◦C, 10 min) positive control, density plots (C,F) are
PAF C-16 treated (100 µg/ml) test conditions. Each plot shows percentage of unstained and PI stained bacteria for different conditions. The difference in
fluorescence intensity for PAF C-16 treated test, solvent treated negative control and heat treated positive control are shown using frequency histogram overlay for
M. smegmatis (G) and M. bovis BCG (H). The blue color histograms represent PAF C-16 treated bacteria, red color is for solvent treated negative control and green
color represents heat treated positive control.
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FIGURE 9 | α-Tocopherol and Tween-80 partially mitigate the growth inhibitory effect of PAF C-16 against M. smegmatis and M. bovis BCG. Number of surviving
colony forming units of M. smegmatis (A,B) and M. bovis BCG (C) after treatment with the indicated concentrations of α-tocopherol/tween-80 and PAF C-16. The
data is expressed as percentage survival where solvent control is taken as 100% survival. Each bar represents the average of three individual experiments performed
in triplicate and the error bars show the standard error of mean values (±SEM). The p-value was calculated by applying Mann-Whitney test on the given two data
sets and was found to be significant ∗(p ≤ 0.05).
attached to terminal amino group), 2-O-methyl PAF (methyl
group at sn-2) and Pyrrolidino PAF (5-member lactam ring
attached to the phosphate group), indicating that these small
modifications had insignificant effects on the bacterial growth
inhibition potential.
Structurally, PAF C-16 is composed of a glycerol backbone
with a single chained aliphatic carbon tail attached via ether
bond at position sn-1, an acetyl group at position sn-2 and
a phosphocholine group attached at sn-3 position (Prescott
et al., 1990; Venable et al., 1993). Different compounds with
structures similar to the phosphocholine head and the aliphatic
carbon tail of PAF C-16 were tested to identify the structurally
active portion of PAF C-16, which might be involved in
the mycobacterial growth inhibition using M. smegmatis as
a model. It seems that the aliphatic carbon chain linked via
oxygen bond to the rest of the molecule is essential for the
anti-mycobacterial activity. This is supported by our results
which showed that compounds containing such a structure
(1-O-hexadecyl-sn-glycerol, miltefosine, and hexadecyl lactate)
possessed anti-mycobacterial activity, whereas palmitic acid
although containing aliphatic carbon chain, but lacking oxygen
bond, showed no such growth inhibitory activity. To the best
of our knowledge, there is currently no information about the
inhibitory effect of these compounds on mycobacterial growth
and our results show a novel activity for these compounds.
Miltefosine has previously been shown to kill Leishmania
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(Jha et al., 1999; Machado et al., 2010), pathogenic bacteria, such
as Streptococcus pneumoniae (Llull et al., 2007) and fungi, such as
Aspergillus fumigatus and Candida species (Widmer et al., 2006;
Biswas et al., 2013). Similarly, hexadecyl lactate has also been
shown to be safe in humans and is used as an additive in food,
medicines, and personal care products (Clary et al., 1998; Zhang
et al., 2010).
Most of the biological activities of PAF C-16 in mammalian
systems are carried out by its binding to specific G-protein
coupled receptors, known as PAFR (Honda et al., 2002; Ishii
et al., 2002). Currently, it is not known if any PAF C-16
receptor exists on bacteria. However, certain activities attributed
to PAF C-16 are independent of its receptor binding, such as
its incorporation into biological membranes, which can affect
the molecular organization of membrane lipids, and hence
membrane functions (Sawyer and Andersen, 1989). In addition,
very limited research has been done to establish the mechanism
through which PAF C-16 can inhibit the growth of prokaryotic
organisms. Exogenous PAF C-16 affects the cell membrane in
Gram-positive bacteria by causing the dysfunction of potassium
ion (K+) transport and leads to the bacterial death but it is
ineffective against Gram-negative bacteria (Steel et al., 2002). In
our study, fluorescence microscopy and flow cytometry analysis
to determine the effect of PAF C-16 on the cell membrane of
M. smegmatis and M. bovis BCG revealed positive PI staining,
which occurred due to the entry of the dye in these bacteria,
indicating damage to the bacterial cell membrane. Furthermore,
prior treatment of the bacteria with α-tocopherol, which is a
well-known anti-oxidant and membrane stabilizer (Kagan, 1989;
Urano et al., 1992), partially mitigated the PAF C-16 induced
bacterial growth inhibition. However, ascorbic acid, another
compound with anti-oxidant properties, failed to prevent PAF
C-16 induced growth inhibition of M. smegmatis (data not
included), suggesting that the protective role of α-tocopherol is
through its membrane stabilizing mechanism. Similarly, another
membrane stabilizing agent tween-80 (Li et al., 2011), also
mitigated the inhibitory effect of PAF C-16 on the growth
of M. smegmatis. This hypothesis is further supported by a
previous study in which tween-80 was shown to reduce the
activity of anti-microbial compounds such as essential oils,
hydrophobic antibiotics like rifampicin and bile salts (Li et al.,
2011; Nielsen et al., 2016). Thus, it is evident that PAF C-
16 mediated growth inhibition of M. smegmatis and M. bovis
BCG is via cell membrane damage, as membrane stabilizing
compounds successfully prevented the PAF C-16 induced growth
inhibition of mycobacteria. However, these membrane stabilizing
compounds also have the ability to form micelles in aqueous
solutions due to their amphipathic nature (Aizawa, 2009) and
there is a possibility that the increased survival of mycobacteria
when treated with both α-tocopherol/tween-80 and PAF C-
16 might be due to the sequestration of PAF C-16 in these
micelles.
In summary, PAF C-16 inhibits the growth of both
M. smegmatis and M. bovis BCG in a dose- and time-dependent
manner. The growth inhibitory effect of PAF C-16 seems to
be through damage to the mycobacterial cell membrane. The
presence of an ether bond at position sn-1 along with a
16 atom carbon chain seems to be important in conferring
the bacterial growth inhibition potential to PAF C-16. Small
structural modifications of PAF C-16 do not affect growth
inhibitory potential against these mycobacteria. Since these
PAF C-16 analogs may lack most of the biological side effects
associated with PAF C-16, they have the potential to be used as
anti-TB drugs. Miltefosine, a compound structurally related to
PAF C-16 investigated in this study, is currently used for treating
Leishmaniasis in humans and has been shown to be well tolerated
at 100 mg orally per day (Sundar et al., 2002; Soto et al., 2004).
Furthermore, these compounds can be delivered via inhaler at a
higher dose directly to the disease site as in the case of pulmonary
TB. In this respect, one of the anti-TB drugs, capreomycin, has
already been tested in a phase I clinical trial in healthy subjects.
In this single-dose escalation study, the maximum dose delivered
was 300 mg by handheld inhaler into the lung with minimum side
effects (Dharmadhikari et al., 2013). It is worthwhile to note that
differences exist between M. tuberculosis and M. bovis BCG (as
well as M. smegmatis) with respect to the composition of the cell
wall components. Therefore, these PAF C-16 structurally related
compounds need further investigation both in vitro and in vivo
using M. tuberculosis.
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